ロード中...
Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
Emicizumab is a factor (F)VIIIa-mimicking bispecific antibody recognizing FIXa and FX molecules. In the phase 1/2 clinical studies, once-weekly subcutaneous administration of emicizumab has shown a favorable safety profile with encouraging efficacy in the patients with hemophilia A (PwHA) irrespecti...
保存先:
| 出版年: | J Blood Med |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6613000/ https://ncbi.nlm.nih.gov/pubmed/31308776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S175952 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|